Nepafenac is a nonsteroidal anti-inflammatory drug indicated for the treatment of pain and inflammation associated with cataract surgery. It is available as ophthalmic suspension. MedsAcross supplies Nepafenac for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
NEVANAC ® 0.1% is indicated for the treatment of pain and inflammation associated with cataract surgery. NEVANAC is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery.
Source: US FDA prescribing information
After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, an NSAID. Amfenac is thought to inhibit the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production.
Source: US FDA prescribing information
One drop of NEVANAC should be applied to the affected eye three times daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period.
Source: US FDA prescribing information
NEVANAC 0.1% is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other non-steroidal anti-inflammatory drugs (NSAIDs). Hypersensitivity to any of the ingredients in the formula or to other non-steroidal anti-inflammatory drugs (NSAIDS).
Source: US FDA prescribing information
Increased bleeding time due to interference with thrombocyte aggregation. Delayed Healing. Corneal effects, including keratitis Increased Bleeding Time With some NSAIDs, including NEVANAC 0.1%, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphema) in conjunction with ocular surgery. It is recommended that NEVANAC 0.1% be used with caution in patients with known bleeding tendencies, or who are receiving other medications, which may prolong bleeding time. Delayed Healing Topical NSAIDs, including NEVANAC 0.1%, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
Source: US FDA prescribing information
The following adverse reactions are discussed in greater detail in other sections of labeling: Increased Bleeding Time Delayed Healing Corneal Effects Most common adverse reactions (5% to 10%) are capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure (IOP), and sticky sensation.
Source: US FDA prescribing information
Store at 2°C to 25°C (36°F to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Nepafenac, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Ilevro 3 mg/mL ophthalmic suspensionOphthalmic | Harrow Eye | US FDA | Available on request |
| Nevanac 1 mg/mL ophthalmic suspensionOphthalmic | Harrow Eye | US FDA | Available on request |
2 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 2 presentations of Nepafenac and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Nepafenac, including Ilevro, Nevanac.
Yes. The US FDA first approved Nepafenac on 19 August 2005, according to Drugs@FDA.
Yes. Nepafenac has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Nepafenac is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Nepafenac is classified under ATC code S01BC10 (Nepafenac).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.